News stories about Imprimis Pharmaceuticals (NASDAQ:IMMY) have been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Imprimis Pharmaceuticals earned a daily sentiment score of 0.14 on Accern’s scale. Accern also gave news stories about the specialty pharmaceutical company an impact score of 45.2660281876376 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Shares of Imprimis Pharmaceuticals (NASDAQ IMMY) remained flat at $$1.72 during midday trading on Thursday. 80,747 shares of the stock traded hands, compared to its average volume of 155,200. Imprimis Pharmaceuticals has a 12 month low of $1.35 and a 12 month high of $4.69. The firm has a market cap of $35.32, a price-to-earnings ratio of -1.86 and a beta of -0.40. The company has a quick ratio of 1.28, a current ratio of 1.67 and a debt-to-equity ratio of 3.94.
Imprimis Pharmaceuticals Company Profile
Imprimis Pharmaceuticals, Inc (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment.
Receive News & Ratings for Imprimis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.